Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3.
| Date | Est. | Actual | |
|---|---|---|---|
| May 9, 2024 | -$0.34 | -$0.73 | Miss |
| Mar 27, 2024 | -$0.42 | -$0.36 | Beat |
| Nov 9, 2023 | -$0.69 | -$0.65 | Beat |
| Aug 8, 2023 | -$0.76 | -$0.68 | Beat |
| May 11, 2023 | -$0.73 | -$0.73 | Beat |
| Mar 15, 2023 | -$0.70 | -$0.72 | Miss |